Table 3.

Outcomes of the study population (N = 678 participants).

Outcomes	Total, N = 678	Low Dosage, n = 452	Regular Dosage, n = 226	Odds Ratio (95% CI)	P value
Incidence of hypoglycemia
M + G	24 (12.3%)	7 (5.3%)	17 (26.6%)	0.16 (0.06–0.40)	<0.001
M + V	7 (5.9%)	1 (1.3%)	6 (14.6%)	0.08 (0.01–0.66)	0.004
M + IG	18 (9.4%)	5 (3.9%)	13 (20.6%)	0.16 (0.05–0.46)	<0.001
M + IG + HRI	22 (12.7%)	6 (5.2%)	16 (27.6%)	0.14 (0.05–0.39)	<0.001
Overall	71 (10.5%)	19 (4.2%)	52 (23.0%)	0.15 (0.08–0.26)	<0.001
Incidence of hyperglycemia
M + G	128 (65.6%)	90 (68.7%)	38 (59.4%)	1.50 (0.81–2.79)	0.4
M + V	89 (75.4%)	59 (76.6%)	30 (73.2%)	1.20 (0.50–2.87)	0.7
M + IG	145 (75.5%)	100 (77.5%)	45 (71.4%)	1.38 (0.70–2.74)	0.5
M + IG + HRI	111 (64.2%)	70 (60.9%)	41 (70.7%)	0.64 (0.33–1.27)	0.4
Overall	473 (69.8%)	319 (70.6%)	154 (68.1%)	1.12 (0.79–1.58)	0.5
Incidence of diabetic ketoacidosis
Overall	0 (0%)	0 (0%)	0 (0%)
Incidence of hyperosmolar hyperglycemic state
Overall	0 (0%)	0 (0%)	0 (0%)

Data are n (%).

M, metformin; G, glimepiride; V, vildagliptin; IG, insulin glargine U100; HRI, human regular insulin.